Chronic Renal Failure, Hyperkalemia
Conditions
Brief summary
Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.In conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. These metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour. The role played by ß2AR polymorphisms in determining the bronchial and vascular response to ß2AR agonist drugs, have been confirmed by several studies. The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled albuterol.
Interventions
DRUGAlbuterol (1,200 μg) through metered-dose inhaler
Sponsors
Hadassah Medical Organization
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients regularly attending the nephrological clinic or the dialysis unit * persistent potassium concentration above 5 mEq/L
Exclusion criteria
1. Patients suffering from active ischemic heart disease 2. Patient with a recent history of arrhythmia 3. Patients treated regularly with ß blockers 4. Patients treated regularly with salbutamol or other ß2AR agonists 5. Patients suffering from persistent tachycardia (pulse \> 100 beats/min) 6. Patients who are hemodynamically unstable 7. Patients suffering from any acute illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The extent of decrease in plasma potassium concentration | — |
| The extent of increase in plasma glucose concentration | — |
| Plasma concentration of albuterol | — |
Countries
Israel
Outcome results
None listed